Showing 2441-2450 of 4063 results for "".
- Ace Vision Group Closes $29.4 Million Series B Financing Roundhttps://modernod.com/news/ace-vision-group-closes-294-million-series-b-financing-round/2482767/Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targ
- Regeneron to Present 27 New Eylea HD Injection 8 mg Abstracts and Presentations at ARVOhttps://modernod.com/news/regeneron-to-present-27-new-eylea-hd-injection-8-mg-abstracts-and-presentations-at-arvo/2482766/Regeneron announced the upcoming presentation of 27 abstracts, including eight oral presentations on Eylea HD (aflibercept) Injection 8 mg in wet age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR). Among the new results and analyses are initia
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im
- Alcon Showcases Five Innovations Across Multiple Specialty Areas at ASCRS 2025https://modernod.com/news/alcon-showcases-five-innovations-across-multiple-specialty-areas-at-ascrs-2025/2482744/Alcon announced its lineup of new product offerings at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, in Los Angeles. This year’s event will feature Alcon’s most recent product introductions across specialty areas rangi
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Lumata Health Secures $23 Million Series B Fundinghttps://modernod.com/news/lumata-health-secures-23-million-series-b-funding/2482691/Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence s
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- DigitalOptometrics to Preview 'World’s First Autonomous Slitlamp' at Vision Expo East 2025https://modernod.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/DigitalOptometrics has announced the launch of what it is calling the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo East (VEE) 2025 in Orlando. In collaboration with SlitLED, DigitalOptometrics will demonstrate t
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili